Literature DB >> 35038147

Cytokines in Renal Cell Carcinoma: A Step Towards Earlier Detection and Targeted Therapy.

Daniela Vargová1, Ján Ľupták2, Ján Dargaj3, Soňa Fraňová1, Michaela Kocmálová4, Juraj Šutovský5, Ján Švihra3, Ingrid Škorňová6, Pavol Slávik7, Marián Grendár8, Ján Švihra3, Lukáš Briš3, Martina Šutovská1.   

Abstract

Symptoms of renal cell carcinoma (RCC) have typically late onset and correlate with its advanced stage. No biomarkers of RCC are currently available. The present study analyzed the immuno-biochemical profile of RCC by measuring the levels of cytokines engaged in RCC pathophysiology. Cytokines were examined by capture sandwich immunoassays in tumor tissue and urine. Specimens of cancer and nearby healthy kidney tissues were obtained during nephrectomy from 60 RCC patients. The urine was obtained from both patients and healthy subjects. The findings in RCC tumor tissue compared to healthy renal tissues were following: (i) increases in interleukin-15 (IL-15), vascular endothelial growth factor (VEGF), interferon gamma-induced protein-10 (IP-10), macrophage inflammatory protein-1β (MIP-1β), monocyte chemoattractant protein-1 (MCP-1), and eotaxin, with VEGF, IP-10, and MIP-1β significantly associated with the histologic tumor nuclear grading (NG); (ii) increases in platelet-derived growth factor (PDGF), IL-15, MIP-1ß, eotaxin, and MCP-1 in urine, with significant associations noticed between cytokines and disease stages for eotaxin and MCP-1; and (iii) decreases in PDGF, IL-15, MCP-1, VEGF, MIP-1β, and eotaxin in urine from six patients on the third day after nephrectomy. We conclude that cytokines may play a critical role in the local pathogenesis of RCC, which opens the way for potential targeting of these molecules in novel therapies and their use as biomarkers for early noninvasive detection of RCC.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Biomarkers; Cytokines; Nephrectomy; Nuclear tumor grading; Renal cell carcinoma; Targeted therapy; Tumor tissue

Mesh:

Substances:

Year:  2022        PMID: 35038147     DOI: 10.1007/5584_2021_700

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

Review 1.  Role of chemokines in renal cell carcinoma.

Authors:  Jaspreet S Parihar; Hari S G R Tunuguntla
Journal:  Rev Urol       Date:  2014

2.  Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells.

Authors:  Xiaoling Luo; Yizhi Yu; Anmin Liang; Yuan Xie; Shuxun Liu; Jun Guo; Wenya Wang; Runzi Qi; Huazhang An; Minghui Zhang; Hongmei Xu; Zhenhong Guo; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2004-06       Impact factor: 11.530

3.  Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting.

Authors:  Stacey L Hembruff; Nikki Cheng
Journal:  Cancer Ther       Date:  2009-04-14

4.  Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.

Authors:  Y Ohta; Y Endo; M Tanaka; J Shimizu; M Oda; Y Hayashi; Y Watanabe; T Sasaki
Journal:  Clin Cancer Res       Date:  1996-08       Impact factor: 12.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.